Stadler R
Department of Dermatology, Medical Centre Minden, Germany.
Dermatol Clin. 1998 Apr;16(2):377-98. doi: 10.1016/s0733-8635(05)70020-6.
Since the first clinical trials in the early 1980s with recombinant interferon, it was possible to show for a variety of indications that cytokines, especially interferons, at certain doses and at respective intervals, when applied in combination with other pharmaceutical compounds open new powerful therapeutic possibilities. Worldwide, recombinant interferon is licensed, especially in dermato-oncology, for the indication of HIV-associated Kaposi's sarcoma, cutaneous T-cell lymphoma, and recently for adjuvant therapy of high-risk malignant melanoma. Recombinant interferon is at present not licensed for dermatologic indication (septic granulomatosis). At the end of our century the indication spectrum for interferons as monotherapy and as combination therapy will undoubtedly be extended. Larger and controlled studies will prove the importance of interferons in dermato-oncology as well as in inflammatory and infectious dermatoses. The combination of interferons with standard therapies will surely be of the utmost importance in dermatotherapy.
自20世纪80年代初首次使用重组干扰素进行临床试验以来，针对多种适应症已证实，细胞因子，尤其是干扰素，在特定剂量和相应间隔下，与其他药物联合使用时，会开启强大的新治疗可能性。在全球范围内，重组干扰素已获许可，尤其在皮肤肿瘤学领域，用于治疗与HIV相关的卡波西肉瘤、皮肤T细胞淋巴瘤，最近还用于高危恶性黑色素瘤的辅助治疗。重组干扰素目前尚未获批用于皮肤病适应症（脓毒性肉芽肿）。在本世纪末，干扰素作为单一疗法和联合疗法的适应症范围无疑将会扩大。规模更大的对照研究将证明干扰素在皮肤肿瘤学以及炎症性和感染性皮肤病中的重要性。干扰素与标准疗法的联合在皮肤病治疗中肯定至关重要。
